Enable Accessibility Enable Accessibility

Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast

October 27, 2022

− Strong Start to Fiscal Year with H1 Core Revenue Growth of +5.5% at Constant Exchange Rate (CER); Reported Revenue Growth +10.1%
− Core Operating Profit Growth of +14.5% at CER; Core Operating Profit Margin of 31.7%
− Reported Operating Profit Growth Affected by One-time Gain Booked in FY2021 Q1 from Sale of Diabetes Portfolio in Japan and FX Impact
− Updating Peak Sales Outlook for ENTYVIO® to $7.5-9.0B
− Net Debt / Adjusted EBITDA Improved to 2.6x; Well-balanced Maturity Profile with 98% of Debt at Fixed Rates at Average 2% Interest
− Upgrading Full-Year Reported and Core Forecasts and Free Cash Flow Outlook, and Reconfirming Management Guidance

Osaka, JAPAN, October 27, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2022 (period ended September 30, 2022), upgrading reported and core forecasts and free cash flow outlook for the fiscal year and reconfirming Management Guidance for core growth at constant exchange rate (CER).

Takeda chief executive officer, Christophe Weber, commented:

“We succeeded in several major milestones in the first half of our fiscal year, including the first approval for Takeda’s dengue vaccine, QDENGA®, in Indonesia and more recently the CHMP positive opinion for Europe and dengue-endemic countries. These milestones, together with our financial results, continue to demonstrate our ability to advance our robust pipeline and deliver new solutions for people and patients around the world.”

Takeda chief financial officer, Costa Saroukos, commented:

“Our first half results are driven by strong momentum from our Growth and Launch Products, which grew at 19% year-on-year at constant exchange rate, and continued success in commercial execution, including new launches, contributing to core profit growth. Our core revenue and core operating profit grew 5.5% and 14.5% at constant exchange rate, respectively, enabling us to reconfirm our Management Guidance for FY2022.

“We have remained resilient amid rising inflation globally as a result of careful, long-term planning and strong execution and we continue to deleverage rapidly, finishing the first half with net debt to adjusted EBITDA at 2.6x, with 98% of our debt at fixed interest rates with a weighted average of 2%.

“We are upgrading our peak sales estimate for our biggest selling product, ENTYVIO®, based on potential for further biologic market growth and share expansion, and our updated assumption for biosimilar entry timing. We are also raising our reported and core forecasts and free cash flow outlook for the full year, primarily reflecting favorable foreign exchange rates.

“We look forward to building on our first half business momentum throughout FY2022.”

FINANCIAL HIGHLIGHTS
Results for FY2022 H1 Ended September 30, 2022

 

(Billion yen, except percentages and per share amounts)

REPORTED

 CORE(c)

(Non-IFRS)(a)

FY2022 H1

vs. PRIOR YEAR
(Actual % change)

FY2022 H1

vs. PRIOR YEAR
(Actual % change)

vs. PRIOR YEAR
(CER % change(d))

Revenue

1,974.8

+10.1%

1,974.8

+18.9%

+5.5%

Operating Profit

255.0

-26.3%

625.2

+28.7%

+14.5%

Margin

 12.9% 

-6.4pp

31.7%

+2.4pp

+2.5pp

Net Profit

166.8

-9.2%

446.7

+33.0%

+14.4%

EPS (yen)

108

-8.1%

288

+34.6%

+15.8%

Operating Cash Flow

305.2

-23.7%

 

 

 

Free Cash Flow (Non-IFRS)(a)(b)

296.9

-5.9%

 

 

 

 

(a) Further information regarding certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/financial-results/.
(b) We define Free Cash Flow as cash flows from operating activities, subtracting acquisition of property, plant and equipment (“PP&E”), intangible assets and investments as well as removing any other cash that is not available to Takeda’s immediate or general business use, and adding proceeds from sales of PP&E, as well as from sales of investments and businesses, net of cash and cash equivalents divested.
(c) Core results adjust our reported results calculated and presented pursuant to IFRS to exclude the effect of items unrelated to Takeda’s core operations, such as, to the extent applicable for each line item, non-recurring items, purchase accounting effects and transaction related costs, as well as amortization and impairment of intangible assets and other operating income and expenses.
(d) CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

 

COMMERCIAL UPDATES ACROSS FIVE KEY BUSINESS AREAS

Growth in our key business areas in the first half of FY2022 was driven largely by Growth & Launch Products1, which delivered revenue of 759.8 billion yen, marking a 19% increase on a CER basis.  

  • Gastroenterology (GI), with 546.4 billion yen in reported revenue, grew +12% on a CER basis driven by 17% global sales growth for ENTYVIO on a CER basis in the first half. Due to this strong performance and other factors, we are raising the peak sales outlook range for ENTYVIO to $7.5-9.0 billion, from a previous estimate of $5.5-6.5 billion.
  • Rare Diseases, with 362.2 billion yen in reported revenue, grew +8% on a CER basis driven by strong sales of hereditary angioedema treatment TAKHZYRO®, which grew 31% year-over-year on a CER basis due to the expansion of the prophylactic market, continued geographic expansion and strong patient uptake. LIVTENCITY™, which launched in the U.S. in December 2021, continues to generate high interest and strong uptake with 75% of U.S. transplant centers having initiated therapy with at least one patient.
  • Plasma-Derived Therapies (PDT) Immunology, with 314.0 billion yen in reported revenue, delivered strong growth of +14% on a CER basis driven by strong demand for Immunoglobulin (+17% growth at CER), particularly in the U.S. amid increasing supply, as well as solid growth for Albumin (+8% at CER) tempered by the impact of lockdowns in China. The PDT business continues to innovate and deliver for patients with life-threatening conditions.
  • Oncology, with 225.3 billion yen in reported revenue, declined -12% on a CER basis as a result of expected entry of multiple VELCADE® generic entrants that began in the U.S. in May 2022. Besides VELCADE, all other revenue totaled 204.5 billion JPY, a year-over-year increase of 6% at CER, led by strong demand for ALUNBRIG® in Japan, Europe and Growth & Emerging Markets, and ADCETRIS®, which continues to gain from increased access and uptake in frontline indications, and ICLUSIG® in the U.S.
  • Neuroscience, with 302.3 billion yen in reported revenue, grew +11% on a CER basis, driven by an expanding ADHD adult market in the U.S. for VYVANSE®/ELVANSE. Sales of TRINTELLIX were 49.8 billion yen (+5% growth at CER), due to continued recovery of the Major Depressive Disorder (MDD) market in the U.S. and strong market share gains in Japan.

 

PIPELINE UPDATE

Takeda has continued to deliver on its ability to bring new therapies to patients and capitalize on momentum within its innovative pipeline. Updates since the FY2022 Q1 announcement include:

  • TAK-003, Takeda’s dengue vaccine candidate, was recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for use in individuals four years of age and older in the European Union (EU) and dengue-endemic countries. This was the CHMP’s first-ever parallel assessment of a medicinal product for use in the EU and non-EU dengue-endemic countries participating in the EU-M4all procedure. Marketing authorization in Europe is expected in the coming months and regulatory reviews are in progress in dengue-endemic countries in Latin America and Asia.
    Additional information related to this announcement is available here.

  • The Indonesia National Agency for Drug and Food Control approved QDENGA® for use in individuals six to 45 years of age regardless of prior dengue exposure. This approval is the first for Takeda’s dengue vaccine candidate and marks the company’s first marketed vaccine outside of Japan. The decision was based on the ongoing Phase 3 TIDES trial that enrolled more than 20,000 children and adolescents living in dengue-endemic countries across Asia and Latin America.
    Additional information related to this announcement is available here.

  • Takeda entered a collaboration and licensing agreement to develop a potential first-in-class therapy for the treatment of celiac disease. TAK-227 is designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease. There are currently no approved therapies for the treatment of celiac disease and Takeda now has three celiac disease programs in Phase 2 development.
    Additional information related to this announcement is available here.

  • The U.S. FDA accepted Takeda’s supplemental biologics license application for TAKHZYRO to prevent hereditary angioedema (HAE) attacks in children from age 2 to <12. If approved, this would be the first and only prophylaxis treatment for HAE patients younger than six years of age.
    Additional information related to this announcement is available here.

  • The EMA’s CHMP recommended the approval of maribavir for adults with post-transplant cytomegalovirus (CMV) refractory (with or without resistance) to prior therapies. If approved, maribavir would be the first and only inhibitor of CMV-specific UL97 protein kinase in the EU for this patient population.
    Additional information related to this announcement is available here.

  • In October, Takeda submitted a new drug application (NDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for its immune globulin subcutaneous (human) 20% solution for use in patients with primary immunodeficiency (PI) or secondary immunodeficiency (SID). Approved as CUVITRU® in more than 30 countries, approval in Japan would offer a new treatment option to patients with agammaglobulinemia or hypogammaglobulinemia. 

 

FY2022 OUTLOOK

Upgrading Full-Year FY2022 Reported and Core Forecasts and Free Cash Flow Outlook, and Reconfirming Management Guidance

Based on Takeda’s first half results, and primarily reflecting expected favorable foreign exchange rates during the remaining second half of FY2022, Takeda’s reported and core forecasts and free cash flow outlook have been revised from the original forecast.

(Billion yen)

FY2022 ORIGINAL FORECAST
(May 2022)

FY2022 REVISED FORECAST (October 2022) 

FY2022 MANAGEMENT GUIDANCE
Core Growth at CER (Non-IFRS)
(Unchanged from May 2022)

Revenue

3,690.0

3,930.0

 

Core Revenue

3,690.0

3,930.0

Low-single-digit growth

Reported Operating Profit

520.0

530.0

 

Core Operating Profit

1,100.0

1,180.0

High-single-digit growth

Reported Net Profit

292.0

307.0

 

Reported EPS (Yen)

188

198

 

Core EPS (Yen)

484

525

High-single-digit growth

Free Cash Flow

600.0 - 700.0

650.0 - 750.0

 

Annual Dividend per Share (Yen)

180

180

 

 

For more details on Takeda’s first half FY2022 results and other financial information including key assumptions in FY2022 forecast and management guidance, please visit: https://www.takeda.com/investors/financial-results/.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

 

Contacts

Investor Relations
Christopher O’Reilly
christopher.oreilly@takeda.com
+81 (0) 3-3278-2543

 

Media Relations
U.S. and International
Megan Ostrower
Megan.Ostrower@takeda.com
+1 (772) 559-4924

 

Japan
Jun Saito
Jun.Saito@takeda.com
+81 (0) 3-3278-2325

 

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Financial information and Certain Non-IFRS Financial Measures

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance and core results, including when controlling for the effect of fluctuations in exchange rates. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures, which are in the financial appendix at the end of Takeda's Q2 FY2022 investor presentation (available at takeda.com/investors/financial-results).

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

1Please refer to slide 19 of Takeda’s FY2022 Q2 investor presentation (available at takeda.com/investors/financial-results) for the definition of Growth & Launch Products.

 

###